Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Hetastarch

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 4 (2)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04845659Phase 4Unknown

Avatrombopaq In Patients With Cirrhosis

NCT03350217Phase 4CompletedPrimary

A Comparison of Eleview Versus Hetastarch as Injectate for EMR

Showing all 2 trials

Research Network

Common Treatments

  • Hetastarch1
  • Avatrombopag Maleate1
  • Eleview1

Active Sponsors

  • Indiana University1
  • Hvidovre University Hospital1

Top Investigators

Related Conditions

  • Postpolypectomy Syndrome1
  • Thrombocytopenia Drugs1
  • Delayed Bleeding1
  • Cirrhosis Liver1
  • Post Procedural Complication1

Activity Timeline